Oculis (OCS) Competitors $15.33 -2.26 (-12.85%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. SWTX, AKRO, CRNX, SRRK, PTGX, CPRX, ALVO, MRUS, IMVT, and MTSRShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Merus (MRUS), Immunovant (IMVT), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Oculis vs. SpringWorks Therapeutics Akero Therapeutics Crinetics Pharmaceuticals Scholar Rock Protagonist Therapeutics Catalyst Pharmaceuticals Alvotech Merus Immunovant Metsera Oculis (NASDAQ:OCS) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Is OCS or SWTX more profitable? SpringWorks Therapeutics has a net margin of -134.73% compared to Oculis' net margin of -8,043.28%. SpringWorks Therapeutics' return on equity of -46.74% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% SpringWorks Therapeutics -134.73%-46.74%-41.12% Which has more volatility and risk, OCS or SWTX? Oculis has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Which has better valuation & earnings, OCS or SWTX? Oculis has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K683.00-$98.92M-$2.31-6.64SpringWorks Therapeutics$191.59M15.46-$325.10M-$3.48-11.35 Does the MarketBeat Community favor OCS or SWTX? SpringWorks Therapeutics received 75 more outperform votes than Oculis when rated by MarketBeat users. However, 91.18% of users gave Oculis an outperform vote while only 71.62% of users gave SpringWorks Therapeutics an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes3191.18% Underperform Votes38.82%SpringWorks TherapeuticsOutperform Votes10671.62% Underperform Votes4228.38% Do analysts rate OCS or SWTX? Oculis currently has a consensus price target of $29.50, indicating a potential upside of 92.43%. SpringWorks Therapeutics has a consensus price target of $73.20, indicating a potential upside of 85.25%. Given Oculis' higher probable upside, equities analysts plainly believe Oculis is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in OCS or SWTX? 22.3% of Oculis shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer OCS or SWTX? In the previous week, Oculis had 1 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 5 mentions for Oculis and 4 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.11 beat Oculis' score of 0.53 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SpringWorks Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySpringWorks Therapeutics beats Oculis on 9 of the 17 factors compared between the two stocks. Remove Ads Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$669.34M$6.43B$5.33B$7.13BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-7.946.8022.8917.40Price / Sales683.00188.30357.5184.53Price / CashN/A65.6738.1634.64Price / Book5.345.636.253.79Net Income-$98.92M$142.11M$3.21B$247.10M7 Day Performance-20.07%-11.37%-8.04%-7.61%1 Month Performance-14.79%-14.47%-2.99%-10.32%1 Year Performance37.49%-18.40%3.54%-7.75% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.0296 of 5 stars$15.33-12.8%$29.50+92.4%+62.7%$669.34M$980,000.00-7.942Gap DownSWTXSpringWorks Therapeutics1.8947 of 5 stars$44.13-6.9%$73.20+65.9%-6.8%$3.31B$191.59M-12.68230Positive NewsGap DownAKROAkero Therapeutics4.1149 of 5 stars$40.48-5.2%$76.29+88.5%+72.5%$3.22BN/A-10.7930Gap DownCRNXCrinetics Pharmaceuticals4.3137 of 5 stars$33.54-3.4%$73.00+117.7%-39.4%$3.12B$1.04M-8.99210News CoveragePositive NewsGap DownHigh Trading VolumeSRRKScholar Rock4.0367 of 5 stars$32.15-2.1%$42.67+32.7%+101.6%$3.04B$33.19M-13.68140News CoveragePositive NewsGap DownPTGXProtagonist Therapeutics3.4941 of 5 stars$48.36-1.1%$62.56+29.4%+65.7%$2.97B$434.43M18.18120Gap DownCPRXCatalyst Pharmaceuticals4.8262 of 5 stars$24.25-1.8%$32.29+33.1%+55.6%$2.95B$491.73M20.5580Positive NewsGap DownALVOAlvotech1.8202 of 5 stars$9.67+1.3%$18.00+86.1%-20.7%$2.92B$391.87M-5.231,026Gap DownMRUSMerus1.847 of 5 stars$42.09-5.6%$85.31+102.7%-6.4%$2.91B$36.13M-10.6637News CoverageGap DownHigh Trading VolumeIMVTImmunovant2.1848 of 5 stars$17.09-7.0%$41.00+139.9%-49.4%$2.90BN/A-6.52120Gap DownHigh Trading VolumeMTSRMetseraN/A$27.22-2.8%$47.00+72.7%N/A$2.86BN/A0.0081Gap Down Remove Ads Related Companies and Tools Related Companies SWTX Competitors AKRO Competitors CRNX Competitors SRRK Competitors PTGX Competitors CPRX Competitors ALVO Competitors MRUS Competitors IMVT Competitors MTSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCS Stock Free OCS Stock Alerts